N-Methyl-8-aminooctansaeure | 856925-83-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-Methyl-8-aminooctansaeure
• 英文别名: 8-(Methylamino)octanoic acid
• CAS: 856925-83-2
• 化学式: C₉H₁₉NO₂
• 分子量: 173.255
• InChiKey: MMPDQZWRFFJSCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-methyl-azonan-2-one 在 盐酸 作用下， 生成 N-Methyl-8-aminooctansaeure
  参考文献：
  名称：

  Masar,B.; Sebenda,J., Collection of Czechoslovak Chemical Communications, 1974, vol. 39, p. 110 - 118

  摘要：

  DOI：

文献信息

• [EN] DENDRITIC CORE COMPOUNDS<br/>[FR] COMPOSÉS À CŒUR DENDRITIQUE
  申请人：CALLAGHAN INNOVATION RES LTD

  公开号：WO2014084743A1

  公开（公告）日：2014-06-05

  The invention relates to compounds that are useful for the preparation of dendrimer compounds, the use of these compounds for preparing dendrimers and processes for preparing the compounds.

  本发明涉及用于制备树枝状化合物有用的化合物，以及使用这些化合物来制备树枝状化合物的方法以及制备这些化合物的过程。
• PYRIMIDINE COMPOUND
  申请人：Matsushima Yuji

  公开号：US20110053912A1

  公开（公告）日：2011-03-03

  A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.

  一种预防和/或治疗与大麻素2型受体相关疾病的新颖优秀方法，基于对大麻素2型受体的激动作用。发现一种异核环衍生物主要具有两个取代基，例如，在2-位置具有取代基氨基的嘧啶-5-羧酰胺衍生物，表现出对大麻素2型受体的强效激动作用，可以成为预防和/或治疗与大麻素2型受体相关疾病，如炎症性疾病、疼痛等的药物。
• [EN] SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE L'HÉMAGGLUTININE DE LA GRIPPE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021202600A1

  公开（公告）日：2021-10-07

  Disclosed are small molecule inhibitors of influenza HA, and methods of using them to treat or prevent HA-mediated diseases and conditions.

  本发明揭示了流感HA的小分子抑制剂，以及使用它们治疗或预防HA介导的疾病和病况的方法。
• Oral GLP-1 Formulations
  申请人：Sarubbi Donald J.

  公开号：US20100016229A1

  公开（公告）日：2010-01-21

  The present invention provides pharmaceutical compositions comprising of at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared to administration of GLP-1 without a delivery agent.

  本发明提供了包含至少一种传递剂和GLP-1的药物组合物。这些药物组合物促进了GLP-1的口服给药，相比于没有传递剂的GLP-1给药，提高了GLP-1的生物利用度（例如，增加了生物利用度）。
• VLA-4 inhibitor compounds
  申请人：Baldwin J. John

  公开号：US20070054909A1

  公开（公告）日：2007-03-08

  Compounds that selectively inhibit the binding of ligands to α4β1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.

  本发明揭示了选择性抑制配体与α4β1整合素（VLA-4）结合的化合物以及它们的制备方法。在一种实施例中，本发明的化合物由式I表示：作为VLA-4介导的细胞黏附的选择性抑制剂，本发明的化合物可用于治疗与此类黏附相关的疾病，包括但不限于炎症和自身免疫反应、糖尿病、哮喘、牛皮癣、炎症性肠病、移植排斥和肿瘤转移等疾病。本发明还揭示了抑制VLA-4介导的细胞黏附的方法以及治疗与VLA-4介导的细胞黏附相关的疾病的方法。